Caricamento...
Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice
BACKGROUND: Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer agents. Previous work revealed that cells from murine osteosarcomas were effic...
Salvato in:
| Pubblicato in: | BMC Cancer |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6744692/ https://ncbi.nlm.nih.gov/pubmed/31521127 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6103-5 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|